Synexa Life Sciences Boosts Bioanalysis Power With Alderley Analytical Acquisition

Synexa Life Sciences, a leader in biomarker and bioanalysis services, has announced its acquisition of Alderley Analytical Ltd, located near Manchester, UK. This acquisition marks a significant milestone in Synexa's growth strategy of "buy and build," reinforcing its goal to be recognized as the preferred scientific partner for biomarker and bioanalytical solutions. Alderley Analytical enhances Synexa Life Sciences’ existing expertise in biomarker and bioanalytical assays, which include analysis of DNA, RNA, proteins, cells, and tissues.

With a focus on mass spectrometry and ligand binding assays, Alderley Analytical provides a comprehensive range of bioanalytical services tailored to support drug development projects at all stages — discovery, preclinical, and clinical for small and large molecules, peptides, oligonucleotides, and biomarkers. Recently, the company relocated to a GLP/GCP-accredited laboratory near Manchester, UK.

Emile Lens, Chief Executive Officer, said in a statement, “Welcoming Alderley Analytical to our group is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and broadening our geographic reach as a leading European specialist biomarker and bioanalysis services company.”

He continued, “By combining two very complementary companies, the group can now offer an even more comprehensive range of services to an enlarged customer base, both in large and small molecule drug development and ranging from pre-clinical work to phase III clinical studies. We are delighted to welcome the Alderley team to Synexa and look forward to combining our strengths.”

Paul Holme, CEO and Co-Founder of Alderley Analytical, said in a statement, “We are thrilled to join forces with Synexa Life Sciences. This step represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”